Breast Cancer

Qualitative interviews with 43 patients on capivasertib plus fulvestrant found the 4-on/3-off dosing schedule broadly acceptable, while identifying gaps in hyperglycemia recognition and willingness to use supportive medications.

This 13-case pictorial review from the University of Rochester Medical Center illustrates the variable mammography, ultrasound, and MRI presentations of pleomorphic invasive lobular carcinoma to support timely interdisciplinary diagnosis.

A panel of exerts discussed key takeaways happening in the field of HER2+ metastatic breast cancer.

This pictorial case series of 5 intramammary spindle-cell lesions demonstrates characteristics that support confident benign diagnosis after biopsy without surgical excision.

This prospective study found that diffuse optical spectroscopy identified elevated collagen as a significant biomarker for breast cancer malignancy, supporting further investigation of DOS as a noninvasive complement to biopsy.

A panel of exerts discussed key takeaways happening in the field of HR+/HER2– breast cancer.

Using spatial proteomics and nanomechanical profiling across two clinical cohorts, investigators identified hypoxia-driven epithelial-to-mesenchymal transition as a biological signature linking aggressive biomechanical phenotypes to poor breast cancer outcomes.

A theory-driven paper planner combined with a digital AI companion demonstrated high acceptability and improved treatment confidence among patients with metastatic TNBC initiating ADC therapy.

In this Florida Cancer Data System mediation analysis, racialized economic segregation and insurance disadvantage explained 29% of the racial disparity in advanced breast cancer stage at diagnosis between Black and White women.

In this Florida Cancer Data System analysis, structural racism and health insurance disadvantage together mediated nearly 8% of the racial disparity in TNBC between Black and White women.

This retrospective claims analysis found neutropenia carried substantial economic burden in HR+/HER2– and triple-negative mBC, with the highest neutropenia-related costs seen during sacituzumab govitecan regimens.

This review of monarchE and TRADE data demonstrates that abemaciclib dose modifications manage treatment-related adverse events without compromising efficacy in high-risk HR+, HER2− early breast cancer.

Treatment with ADCs for metastatic TNBC comes with a unique set of toxicities, and know how to manage, or adjust treatment as needed is important.

This descriptive systematic review of 14 studies found diagnostic delay in PABC was common and multifactorial, driven by both patient- and provider-related factors including symptom misattribution to pregnancy.

This phase 1/2 trial assessed HER2 BATs combined with pembrolizumab in metastatic breast cancer, finding the regimen safe and well tolerated with stable disease as the best response in 17 evaluable patients.

Panelists discussed 4 trials, which focused on 3 different ADCs and how each one is being utilized in their clinical practice.

This prospective, single-arm observational trial examines whether aromatase inhibitor therapy in postmenopausal women with HR-positive breast cancer adversely affects cardiorespiratory fitness, skeletal muscle function, and immunosenescence.

This randomized multicenter pilot trial assesses feasibility of the THRIVE Wellness Program, a 6-week lifestyle intervention for young breast cancer survivors aged 40 years or younger.

Survey of safety-net breast cancer patients links stronger faith to greater trust in doctors, especially among Black and lower-income groups.

Explore how breast cancer stem cell plasticity, epigenetic reprogramming, and single-cell insights drive therapy resistance, revealing new targets to improve durable responses.

Explore how newer HER2 therapies and anthracycline-sparing regimens cut breast cancer heart damage, with monitoring and cardioprotective drugs.

Real-world study shows T-DXd benefits older metastatic breast cancer patients, but higher ILD risk and toxicity-driven discontinuation demand close monitoring, especially in octogenarians.

Does infusion timing matter in TNBC? Early-day pembrolizumab may boost pCR and cut recurrences, prompting new scheduling questions.

Clonal blood mutations common in breast cancer may sharply raise heart failure risk after anthracyclines, urging better screening and personalized cardio-oncology care.

Explore how ADCs reshape breast cancer care, with practical sequencing strategies across subtypes and guideline-based toxicity management for ILD, neutropenia, and GI effects.